BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neirinckx V, Hau AC, Schuster A, Fritah S, Tiemann K, Klein E, Nazarov PV, Matagne A, Szpakowska M, Meyrath M, Chevigné A, Schmidt MHH, Niclou SP. The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma. Neurooncol Adv 2019;1:vdz024. [PMID: 32642659 DOI: 10.1093/noajnl/vdz024] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Hu J, Dong F, He Y, Xia X, Cheng F, Chen S, Hou X, Zhang P, Liu G, Li Y, Gao Q, Dong M, Li T, Li W, Xiao Q, Li X, Yu X, Xi G, Guo D, Wu X, Wang B. LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization. J Immunother Cancer 2022;10:e004452. [PMID: 36096529 DOI: 10.1136/jitc-2021-004452] [Reference Citation Analysis]
2 Ji Y, Kumar R, Gokhale A, Chao HP, Rycaj K, Chen X, Li Q, Tang DG. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. Semin Cancer Biol 2021:S1044-579X(20)30276-5. [PMID: 33476721 DOI: 10.1016/j.semcancer.2020.12.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]